Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine
ZIOPHARM Oncology Inc (ZIOP)
Last ziopharm oncology inc earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ziopharm.com
Company Research
Source: GlobeNewswire
– Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma –– Median overall survival for Controlled IL-12 in patients receiving low-dose steroids was 17.8 months – – Increased tumor infiltrating lymphocytes and PD-1 (programmed cell death protein 1) support immunological anti-tumor effect of Controlled IL-12 – BOSTON, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the publication of its phase 1 trial of Controlled IL-12 in patients with recurrent glioma in the journal Science Translational Medicine. The publication entitled, “Regulatable interleukin 12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial” can be accessed at https://stm.sciencemag.org/. While IL-12 is known as a potent immune activator that triggers T cells to target cancer, historic trials sy
Show less
Read more
Impact Snapshot
Event Time:
ZIOP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZIOP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZIOP alerts
High impacting ZIOPHARM Oncology Inc news events
Weekly update
A roundup of the hottest topics